

ARTICLE OPEN



Clinical Studies

Anti-integrin $\alpha\beta6$ autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis

Masataka Yokode¹, Masahiro Shiokawa^{1,8}, Hisato Kawakami^{1,2,8}, Takeshi Kuwada¹, Yoshihiro Nishikawa¹, Yuya Muramoto¹, Hiroki Kitamoto¹, Makoto Okabe¹, Hajime Yamazaki³, Norihiro Okamoto⁴, Toshihiro Morita⁵, Kazuya Ohno⁶, Risa Nakanishi¹, Ikuhisa Takimoto¹, Muneji Yasuda¹, Koki Chikugo¹, Shimpei Matsumoto¹, Hiroyuki Yoshida¹, Sakiko Ota¹, Takeharu Nakamura¹, Hirokazu Okada¹, Tomonori Hirano¹, Nobuyuki Kakiuchi¹, Tomoaki Matsumori¹, Shuji Yamamoto¹, Norimitsu Uza¹, Makoto Ooi⁴, Yuzo Kodama⁴, Tsutomu Chiba⁷, Hidetoshi Hayashi¹ and Hiroshi Seno¹

© The Author(s) 2024

BACKGROUND: No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin $\alpha\beta6$ autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis.

METHODS: Serum anti-integrin $\alpha\beta6$ autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin $\alpha\beta6$ autoantibodies in the ICI-induced colitis patients were compared with those of UC patients.

RESULTS: Anti-integrin $\alpha\beta6$ autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls ($P < 0.001$). Patients with anti-integrin $\alpha\beta6$ autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies ($P < 0.001$). Anti-integrin $\alpha\beta6$ autoantibodies in ICI-induced colitis patients were associated with grade ≥ 3 colitis ($P = 0.001$) and steroid resistance ($P = 0.005$). Anti-integrin $\alpha\beta6$ autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin $\alpha\beta6$ autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC.

CONCLUSIONS: Anti-integrin $\alpha\beta6$ autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis.

British Journal of Cancer; <https://doi.org/10.1038/s41416-024-02647-1>

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have revolutionized tumor treatment strategies, showing significant efficacy against diverse malignancies [1]. However, inhibiting immune checkpoints can cause inflammation in various organs, leading to immune-related adverse events (irAEs) that resemble autoimmune diseases [2, 3]. With the increasing use of ICIs in cancer treatment regimens, the incidence of newly diagnosed irAEs continues to rise. ICI-induced colitis, the most common form of gastrointestinal (GI) irAEs, shows a broad spectrum of disease severity, endoscopic findings, and therapeutic responses [4, 5]. Rapid diagnosis followed by adequate immunosuppression with corticosteroids is essential for the treatment of moderate to severe ICI-induced colitis [4, 5]. However, an early switch to stronger immunosuppressive

therapies, such as infliximab and vedolizumab, is required in cases with steroid-refractory ICI-induced colitis, which can cause life-threatening complications including colorectal perforation and subsequently, unfavorable patient outcomes [4, 5]. Therefore, reliable and objective biomarkers for the diagnosis, monitoring, and risk management of ICI-induced colitis are crucial for achieving favorable patient outcomes; however, thus far, no specific biomarkers for this condition have been identified.

Some studies have demonstrated the endoscopic and histopathological similarities between ICI-induced colitis and inflammatory bowel disease (IBD) [6–11]. However, whether IBD-like ICI-induced colitis has a similar pathophysiology to IBD remains to be elucidated. We recently identified anti-integrin $\alpha\beta6$ autoantibodies in Japanese patients with ulcerative colitis (UC), the most

¹Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan. ²Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. ³Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ⁴Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan. ⁵Department of Gastroenterology and Hepatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan. ⁶Department of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan. ⁷Department of Gastroenterology and Hepatology, Kansai Electric Power Hospital, Osaka, Japan. ⁸These authors contributed equally: Masahiro Shiokawa, Hisato Kawakami.

✉ email: machan@kuhp.kyoto-u.ac.jp; kawakami_h@med.kindai.ac.jp




Fig. 1 Detection of anti-integrin $\alpha v \beta 6$ autoantibodies in serum samples of patients with ICI-induced colitis. Serum IgG antibodies against integrin $\alpha v \beta 6$ were quantified using ELISA. The sera of 26 patients with ICI-induced colitis, 39 ICI-treated patients with other types of irAEs (18 with hepatitis, 11 with endocrine dysfunction, 6 with pneumonitis, 4 with other irAEs), 77 patients with cancer without irAEs (16 with colon cancer, 15 with non-small cell lung cancer, 15 with gastric cancer, 15 with bile duct cancer, 12 with pancreatic cancer, 4 with melanoma), and 41 healthy volunteers were examined (Supplementary Table S1, Supplementary Table S3). IgG antibodies against integrin $\alpha v \beta 6$ were identified in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls. The cutoff OD value, defined as the mean plus three SDs of sera from the healthy volunteers, is indicated using a dashed line. The experiment was repeated independently twice with similar results. ELISA enzyme-linked immunosorbent assay, ICI immune checkpoint inhibitor, IgG immunoglobulin G, irAEs immune-related adverse events, OD optical density, SD standard deviation.

common type of IBD [12]. Remarkably, the sensitivity and specificity of these autoantibodies for UC are both >90% and those titers are correlated with the disease activity of UC [12]. These results are replicated in studies in United States and Sweden by other groups [13, 14], further supporting the reliability of anti-integrin $\alpha v \beta 6$ autoantibodies as a diagnostic and disease activity marker for UC.

Integrins are a major family of heterodimeric cell adhesion receptors comprising 18 α - and 8 β - subunits that form 24 distinct integrin heterodimers [15]. Among them, integrin $\alpha v \beta 6$ has been reported to be present in the intestine, bind to extracellular matrix proteins such as fibronectin [16], and play an important role in maintaining epithelial barrier function [17]. Furthermore, integrin $\alpha v \beta 6$ is also widely expressed in various types of cancer [18].

In this study, given the similarities between ICI-induced colitis and IBD, we examined whether patients with ICI-induced colitis also possess anti-integrin $\alpha v \beta 6$ autoantibodies, and found that certain patients with ICI-induced colitis have these autoantibodies. We also investigated the clinical features of such patients. This study will provide insight into the pathogenesis and heterogeneity of ICI-induced colitis.

MATERIALS AND METHODS

Patients

This was a retrospective study targeting patients with ICI-induced colitis who had undergone colonoscopy at the onset of the disease at Kyoto University Hospital, affiliated hospitals, and Kindai University Faculty of Medicine between April 2018 and April 2023. All but one patient (Case 1) was treated with only ICI treatment. ICI-induced colitis was defined as diarrhea or bloody stools following ICI administration and/or with histological evaluation [5]. Patients with preexisting IBD and infectious enteritis caused by pathogenic microorganisms, such as *Clostridioides difficile*, *Campylobacter jejuni*, and *Cytomegalovirus*, were excluded. The severity of ICI-induced colitis was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [19]. The clinical characteristics of each patient with ICI-induced colitis such as age, sex, ICI medication, cancer type, time from ICI initiation to onset, CTCAE grade of diarrhea and colitis, treatment for irAE, comorbidities, other irAEs, and prognosis are shown in Supplementary Table S1 and summarized in Supplementary Table S2. Serum samples were collected from each patient at the time of diagnosis. Among them, serial blood samples were available in four patients with ICI-induced colitis (Case 1, 10, 14, and 20), and the

disease activity of the four patients was evaluated using the full or partial Mayo score [20]. Serum samples were also collected from 39 patients with irAEs in other organs, 77 patients with cancer but without irAEs, and 41 healthy volunteers as controls (Supplementary Table S3). Sera from 12 patients with UC were used to compare autoantibody characteristics between ICI-induced colitis and UC (Supplementary Table S4). All serum samples were stored at -80°C until assayed.

The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (protocol number: R1004). All participants provided written informed consent.

Analysis of endoscopic findings

Two experienced endoscopists (M.O. and H.K.) who were blinded to the anti-integrin $\alpha v \beta 6$ antibody titer evaluated endoscopic findings. Both endoscopists majored in IBD and had over 10 years of work experience. The endoscopic findings of the patients were classified into typical UC findings as described in Supplementary Table S5 [21]. The presence or absence of the endoscopic findings in each patient was scored as 1 or 0, respectively, and the total score was calculated (Supplementary Table S6). The average of the scores assigned by the two endoscopists was used for further analysis.

Enzyme-linked immunosorbent assay

Recombinant human integrin heterodimers were purchased from ACROBiosystems (Newark, DE, USA), and recombinant human integrin $\beta 6$ monomer was kindly provided by Medical and Biological Laboratories (Tokyo, Japan) (Supplementary Table S7). To detect serum immunoglobulin G (IgG) antibodies against integrins, we used an enzyme-linked immunosorbent assay (ELISA) Starter Accessory kit (E101, Bethyl Laboratories, Montgomery, TX, USA) according to the manufacturer's instructions. Briefly, microtiter plates were coated with 100 μL of the recombinant proteins (2 $\mu\text{g}/\text{mL}$) overnight at 4°C , blocked, and incubated for 60 min with 100 μL of diluted serum (1:100) at room temperature. After five washes with wash solution, the plates were incubated for 60 min with 100 μL rabbit anti-human IgG antibody conjugated with horseradish peroxidase (HRP) (1:50,000; ab6759, Abcam, Cambridge, UK) at room temperature. After additional five washes with wash solution, the bound reactants were identified by incubating with 3,3',5,5'-tetramethylbenzidine (TMB) for 7 min at room temperature. The absorbance was measured at 450 nm. ELISA was performed with MgCl_2 and CaCl_2 (1 mM each) [12].

The subclasses of the autoantibodies were identified using anti-human IgG1, IgG2, IgG3, and IgG4 secondary antibodies conjugated with HRP (1:2,000; BS-AP006, BS-AP007, BS-AP008, and BS-AP009, respectively; The

Table 1. Comparison between anti-integrin $\alpha\text{v}\beta 6$ antibody-positive and anti-integrin $\alpha\text{v}\beta 6$ antibody-negative patients with ICI-induced colitis.

	Anti-integrin $\alpha\text{v}\beta 6$ antibodies		P value
	Positive	Negative	
Number of patients, n	8	18	
Median age, years (range)	69 (57–82)	70.5 (47–80)	0.404
Sex			
Male, n (%)	5 (62.5)	13 (72.2)	0.667
Female, n (%)	3 (37.5)	5 (27.8)	
Endoscopic findings			
Number of typical UC findings (median)	4.5	1.5	<0.001
Cancer type, n (%)			
Non-small cell lung cancer	2 (25)	6 (33.3)	0.815
Melanoma	3 (37.5)	4 (22.2)	
Kidney cancer	1 (12.5)	4 (22.2)	
Esophageal cancer	1 (12.5)	1 (5.6)	
Peritoneal cancer	1 (12.5)	0 (0)	
Cancer of unknown primary	0 (0)	1 (5.6)	
Malignant pleural mesothelioma	0 (0)	1 (5.6)	
Bladder cancer	0 (0)	1 (5.6)	
ICI medication, n (%)			
Pembrolizumab	4 (50)	6 (33.3)	0.429
Nivolumab	3 (37.5)	5 (27.8)	
Nivolumab and ipilimumab	0 (0)	5 (27.8)	
Atezolizumab	1 (12.5)	1 (5.6)	
Durvalumab	0 (0)	1 (5.6)	
Grade ≥ 3 adverse events, n (%)			
Diarrhea	5 (62.5)	7 (38.9)	0.401
Colitis	6 (75)	1 (5.6)	0.001
Treatment, n (%)			
Steroid alone	3 (37.5)	12 (66.7)	0.218
Conservative treatment	1 (12.5)	6 (33.3)	0.375
Steroid/infliximab	4 (50)	0 (0)	0.005
Prognosis, n (%)			
Alive	4 (50)	12 (66.7)	0.664
Dead	4 (50)	6 (33.3)	

Severity of diarrhea and colitis was assessed according to CTCAE version 5.0 [19].

Binding Site, Birmingham, UK). In addition, the autoantibody isotypes were evaluated using anti-human IgA, IgM, and IgE secondary antibodies conjugated with HRP (1:50,000 A80-102P, 1:100,000 A80-100P, and 1:1,000 A80-108P, respectively; Bethyl Laboratories).

To investigate whether the Arg-Gly-Asp (RGD) peptide inhibited the binding of IgG obtained from patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies against integrin $\alpha\text{v}\beta 6$, we added the Arg-Gly-Asp-Ser (RGDS) peptide (A9041, Sigma-Aldrich, St. Louis, MO, USA) or the control peptide Arg-Gly-Glu-Ser (RGES) (A5686, Sigma-Aldrich) to the serum at concentrations of 25 and 100 $\mu\text{g}/\text{mL}$ before incubation.

Isolation of human immunoglobulin G

IgG was isolated from the sera of patients and healthy volunteers using Ab-Rapid SPIN EX (P-014; ProteNova, Higashikagawa, Japan) and stored at -30°C . In our previous study, the rate of IgG recovery from the sera was verified to be $>90\%$ [12, 22].

Solid-phase integrin $\alpha\text{v}\beta 6$ binding assay

A solid-phase integrin $\alpha\text{v}\beta 6$ binding assay was performed following a previously described method with minor modifications [12, 23]. Briefly, a 96-well microtiter plate was coated with 100 $\mu\text{L}/\text{well}$ integrin $\alpha\text{v}\beta 6$ (2 $\mu\text{g}/\text{mL}$) overnight at 4°C , blocked, and incubated with 100 μL of diluted patient or control IgG (1:10) for 60 min at room temperature. After five washes with wash solution, the plates were incubated with 100 μL fibronectin (2 $\mu\text{g}/\text{mL}$; FC010, Millipore Sigma, Burlington, MA, USA) for 60 min at room temperature. After five washes with wash solution, an anti-fibronectin antibody (1:5,000; ab2413, Abcam) was added, followed by incubation for 60 min at room temperature. Afterward, the plates were washed with wash solution five times, and an anti-rabbit IgG HRP-conjugated secondary antibody (1:10,000; A27036, Thermo Fisher Scientific, MA, USA) was added, followed by incubation for 60 min at room temperature. The plates were washed (five times with wash solution), incubated with TMB for 10 min at room temperature, and bound reactants were identified. The absorbance was measured at 450 nm. A solid-phase integrin $\alpha\text{v}\beta 6$ binding assay was performed in the presence of MgCl_2 and CaCl_2 (1 mM each).

The inhibition rate was calculated as follows: [(control optical density (OD) – sample OD)/control OD]. The control OD was measured by coating the control wells with integrin $\alpha\text{v}\beta 6$ and incubating with fibronectin in the absence of patient or control IgG.

Immunohistochemical analysis

The immunohistochemical analysis was performed according to standard procedures for human tissue sections. Because integrin $\beta 6$ forms a dimer only with integrin αv , whereas, αv can dimerize with other β subunits, including $\beta 1$, $\beta 3$, $\beta 5$, and $\beta 8$ [24], antibodies against integrin $\beta 6$ were used to detect integrin $\alpha\text{v}\beta 6$ expression. Antigen retrieval was performed on sections by incubating them in citrate buffer (pH 6.0) for 20 min at 121°C in an autoclave before incubating overnight at 4°C with the antibodies against integrin $\beta 6$ (1:500; HPA023626, Sigma-Aldrich). Liquid DAB+ Substrate Chromogen System (K3468, Dako, Santa Clara, CA, USA) was used for staining. Detection times were equally standardized for all sections. Staining intensity of integrin $\beta 6$ was graded as either 0, 1+, 2+, or 3+. The H-score was calculated using the following formula: $[1 \times (\% \text{ cells } 1+) + 2 \times (\% \text{ cells } 2+) + 3 \times (\% \text{ cells } 3+)]$.

Statistical analysis

Fisher's exact test was performed to evaluate categorical variables. Continuous variables were compared using Mann-Whitney U tests. Intraclass correlation coefficient (ICC) was used to determine the reliability of the endoscopic scores determined by the two endoscopists. GraphPad Prism Version 9 (GraphPad Software, San Diego, CA, USA) and Stata 18 (StataCorp, College Station, TX, USA) were used for statistical analysis. Two-tailed $P < 0.05$ was considered statistically significant.

RESULTS

Clinical characteristics of patients with ICI-induced colitis

Twenty-six patients clinically diagnosed with ICI-induced colitis and undergoing colonoscopy at the onset of the disease were enrolled in the study. The baseline clinical characteristics of the patients with ICI-induced colitis are summarized in Supplementary Table S2. The median age of patients at the onset of ICI-induced colitis was 69.5 years (range: 47–82 years). There were 18 men and eight women. Eighteen (69.2%) patients were treated with PD-1 inhibitors, five (19.2%) with CTLA-4 and PD-1 inhibitors, and three (11.5%) with PD-L1 inhibitors. The median time from treatment initiation to ICI-induced colitis onset was 108 days (range: 14–837 days). Furthermore, 12 (46.2%) patients had grade ≥ 3 diarrhea, while seven (26.9%) developed grade ≥ 3 colitis based on symptoms. Fifteen (57.7%) patients were treated with steroids alone, whereas four (15.4%) were treated with steroids plus




Fig. 2 Differences in endoscopic findings between patients with ICI-induced colitis with and without anti-integrin $\alpha\text{v}\beta 6$ autoantibodies. **a** Endoscopic images of patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies revealed findings similar to those of UC, including erythema, granularity, decreased vascular pattern, bleeding, and ulcer formation (Supplementary Table S5). In contrast, negative cases showed findings atypical of UC, such as punched ulcers. All patients underwent colonoscopy at the onset of the disease. **b** The average total number of typical UC findings assessed by two endoscopists was significantly higher in patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies compared to that in those without autoantibodies (median scores, 4.5 vs. 1.5; $P < 0.001$). The horizontal lines represent the median. ICI immune checkpoint inhibitor, UC ulcerative colitis.

infliximab. Seven (26.9%) patients improved with conservative treatment alone. With regard to prognosis, 10 (38.5%) patients had died because of the progression of primary malignancies at the time of analysis (median follow-up time of 25 months [range: 4–61 months]).

Detection of anti-integrin $\alpha\text{v}\beta 6$ autoantibodies in patients with ICI-induced colitis

We performed ELISA to identify anti-integrin $\alpha\text{v}\beta 6$ autoantibodies in patients with ICI-induced colitis. Based on a cutoff OD of the mean plus three standard deviations of healthy volunteer sera, eight (30.8%; 8/26) patients with ICI-induced colitis were identified positive for IgG autoantibodies against integrin $\alpha\text{v}\beta 6$. In contrast, similar IgG autoantibodies were identified in 3 controls (1.9%; 3/157) (Fig. 1). Anti-integrin $\alpha\text{v}\beta 6$ autoantibodies had a sensitivity and specificity of 30.8% and 98.1%, respectively, in patients with ICI-induced colitis ($P < 0.001$). The specificity of anti-integrin $\alpha\text{v}\beta 6$ autoantibodies for patients with ICI-induced colitis compared with that for patients with other irAEs or those with cancer without irAEs was 97.4% ($P = 0.002$) and 97.4% ($P < 0.001$), respectively. Eight out of 21 (38.1%) ICI-induced colitis patients treated with PD-1/PD-L1 inhibitor monotherapy were positive for the

autoantibodies, while all five ICI-induced colitis patients treated with combination of CTLA-4 and PD-1 inhibitors were negative for the autoantibodies (Table 1).

UC-like endoscopic findings and severe symptoms for patients with ICI-induced colitis possessing anti-integrin $\alpha\text{v}\beta 6$ autoantibodies

Next, we compared endoscopic findings and clinical characteristics between patients with ICI-induced colitis with or without anti-integrin $\alpha\text{v}\beta 6$ autoantibodies. Independent blinded assessment revealed that the endoscopic findings were more similar between patients with autoantibodies and those with UC than those in patients without autoantibodies (Fig. 2a). Furthermore, the average score of typical UC findings was significantly higher in patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies than that in those without the autoantibodies (median scores, 4.5 vs. 1.5; $P < 0.001$) (Fig. 2b, Table 1, Supplementary Table S5, Supplementary Table S6). The ICC of endoscopic scores estimated by the two endoscopists was 0.85 (95% confidence interval, 0.56–0.94). Anti-integrin $\alpha\text{v}\beta 6$ autoantibodies in patients with ICI-induced colitis were significantly associated with CTCAE grade ≥ 3 colitis (6/8, 75% vs. 1/18, 5.6%; $P = 0.001$; Table 1).




Fig. 3 Correlation between anti-integrin $\alpha v \beta 6$ autoantibody titers and disease activity in patients with ICI-induced colitis with anti-integrin $\alpha v \beta 6$ autoantibodies. Serial blood samples from four patients with ICI-induced colitis with anti-integrin $\alpha v \beta 6$ autoantibodies (Case 1, 10, 14, and 20) were used. Changes in autoantibody titers against integrin $\alpha v \beta 6$ in ICI-induced colitis patients with anti-integrin $\alpha v \beta 6$ autoantibodies correlated with the changes in the full or partial Mayo score. The left y-axis and the red points represent the OD values of anti-integrin $\alpha v \beta 6$ serum IgG levels, while the right y-axis and the blue points represent the full or partial Mayo score. ICI immune checkpoint inhibitor, IgG immunoglobulin G, OD optical density.

In addition to steroids, infliximab treatment was required only for the patients with anti-integrin $\alpha v \beta 6$ autoantibodies (4/8, 50% vs. 0/18, 0%; $P = 0.005$; Table 1). These findings suggest that anti-integrin $\alpha v \beta 6$ autoantibodies are potential markers to identify ICI-induced colitis harboring UC-like endoscopic findings and severe symptoms that require stronger immunosuppressive therapy.

Correlation between anti-integrin $\alpha v \beta 6$ autoantibody titers and disease activity

Changes in anti-integrin $\alpha v \beta 6$ antibody titers were investigated using serially collected serum samples from four patients with ICI-induced colitis who were positive for the autoantibodies. The full or partial Mayo score corresponded with changes in antibody titers against integrin $\alpha v \beta 6$ in patients with ICI-induced colitis (Fig. 3). These findings suggest that anti-integrin $\alpha v \beta 6$ autoantibody titers reflect disease activity in patients with ICI-induced colitis resembling UC.

Similar antibody characteristics between patients with ICI-induced colitis and those with UC in subclass, isotype, epitope, and functions

We investigated the characteristics of anti-integrin $\alpha v \beta 6$ autoantibodies in the patients with ICI-induced colitis and compared them to those in UC. We previously found that anti-integrin $\alpha v \beta 6$ autoantibodies in UC patients show a predominance of the IgG1 subclass and IgA isotype [12]. In this study, ELISA results showed that seven and eight of the eight patients with ICI-induced colitis positive for the antibody had IgG1 and IgA autoantibodies, respectively (Supplementary Fig. S1). These data in patients with ICI-induced colitis were similar to those in patients with UC.

We also checked the similarity of epitope of anti-integrin $\alpha v \beta 6$ autoantibodies between ICI-induced colitis and UC patients. We examined whether the integrin $\alpha v \beta 6$ autoantibodies might

recognize integrin $\alpha v \beta 6$ dimer, or monomers of integrin αv or integrin $\beta 6$. We were able to obtain a monomer of integrin $\beta 6$ that was verified by ELISA (Supplementary Fig. S2). However, we could not obtain a monomer of integrin αv . Therefore, we assayed the serum samples for autoantibodies against integrin $\alpha v \beta 1$, $\alpha v \beta 3$, $\alpha v \beta 5$, or $\alpha v \beta 8$ to assess the reactivity with integrin αv . Six (75%) patients with anti-integrin $\alpha v \beta 6$ autoantibodies had anti-integrin $\alpha v \beta 3$ autoantibodies similar to patients with UC [12], but none had autoantibodies against other αv -containing integrins and monomer of integrin $\beta 6$ (Supplementary Fig. S3). These results suggest that the anti-integrin $\alpha v \beta 6$ autoantibodies of both patients with ICI-induced colitis and UC bind to dimeric conformation of integrin $\alpha v \beta 6$.

As shown in Supplementary Fig. S4a, integrin $\alpha v \beta 6$ binds to its ligands, such as fibronectin, through the RGD tripeptide motif [25]. In this study, solid-phase binding assay revealed that IgG from six of eight (75%) patients with ICI-induced colitis with anti-integrin $\alpha v \beta 6$ autoantibodies blocked integrin $\alpha v \beta 6$ -fibronectin binding (Fig. 4a, Supplementary Fig. S4b). These findings are consistent with those of our previous study, which showed that IgG purified from patients with UC blocked integrin $\alpha v \beta 6$ -fibronectin binding [12].

Furthermore, similar to our previous study, we showed that RGD peptides inhibited the binding of IgG of patients with ICI-induced colitis with anti-integrin $\alpha v \beta 6$ autoantibodies to integrin $\alpha v \beta 6$ in a dose-dependent manner (Fig. 4b, Supplementary Fig. S4c). However, RGEs peptides (control) did not inhibit this binding (Fig. 4c). These results suggest that like that in patients with UC, anti-integrin $\alpha v \beta 6$ autoantibodies in patients with ICI-induced colitis bind to the RGD binding site of integrin $\alpha v \beta 6$.

Altogether, these findings suggest that anti-integrin $\alpha v \beta 6$ autoantibodies in patients with ICI-induced colitis show similar characteristics to those in patients with UC [12].




Fig. 4 Blocking of integrin $\alpha\text{v}\beta 6$ -fibronectin binding by IgG from patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies. **a** Inhibition of integrin $\alpha\text{v}\beta 6$ -fibronectin binding by IgG of patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies in the solid-phase binding assay. The cutoff OD value, defined as the mean plus three SDs of IgG from healthy volunteers, is indicated using a dashed line. IgG from six of eight (75%) patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies blocked integrin $\alpha\text{v}\beta 6$ -fibronectin binding. However, no control IgG showed blocking activity. **b, c** Peptide RGDS, but not RGEs, dose-dependently impaired the binding of IgG of patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies against integrin $\alpha\text{v}\beta 6$. The RGDS and RGEs peptides represented the RGD and RGE motifs, respectively. The experiments were repeated independently twice with similar results. ICI immune checkpoint inhibitor, IgG immunoglobulin G, OD optical density, RGD Arg-Gly-Asp, RGDS Arg-Gly-Asp-Ser, RGE Arg-Gly-Glu, RGEs Arg-Gly-Glu-Ser, SD standard deviation.

Expression of integrin $\alpha\text{v}\beta 6$ in tumor tissues of the patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies

Next, we investigated whether the primary tumors of patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies express integrin $\alpha\text{v}\beta 6$, given that production of autoantibodies may be induced by the immune reaction to primary tumors. Immunohistochemical analysis revealed that all eight patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies had tumors that expressed integrin $\alpha\text{v}\beta 6$. By contrast, integrin $\alpha\text{v}\beta 6$ expression was less frequent in patients without anti-integrin $\alpha\text{v}\beta 6$ autoantibodies (8/8, 100% vs. 5/10, 50%; $P = 0.036$; Fig. 5a). Moreover, the H-score for integrin $\beta 6$ immunostaining was significantly higher in the tumors of patients with ICI-induced colitis with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies than that in those without the autoantibodies (median scores, 210 vs. 35; $P = 0.018$;

Fig. 5b). These findings may indicate a causal association between integrin $\alpha\text{v}\beta 6$ expression in the primary tumor and anti-integrin $\alpha\text{v}\beta 6$ autoantibodies in the serum.

DISCUSSION

In this study, we found that a part of ICI-induced colitis patients possessed anti-integrin $\alpha\text{v}\beta 6$ autoantibodies and such patients exhibited endoscopically UC-like colitis with severe symptoms that required intensive therapy. The titers of anti-integrin $\alpha\text{v}\beta 6$ autoantibodies correlated with disease activity of ICI-induced colitis. Anti-integrin $\alpha\text{v}\beta 6$ autoantibodies in patients with ICI-induced colitis had similar characteristics to those in patients with UC. Moreover, immunohistochemistry analysis revealed integrin $\alpha\text{v}\beta 6$ expression in tumor tissues of all patients with anti-integrin $\alpha\text{v}\beta 6$ autoantibodies.




Fig. 5 Expression of integrin αvβ6 in tumor tissues of the patients with ICI-induced colitis with and without anti-integrin αvβ6 autoantibodies. **a** Representative H&E staining and immunohistochemical staining of integrin β6 in tumors of ICI-induced colitis patients with or without integrin αvβ6 autoantibodies. Scale bars, 100 μm. **b** H-score for integrin β6 immunostaining in tumors of patients with ICI-induced colitis with or without integrin αvβ6 autoantibodies. Horizontal lines indicate median values. The experiments were repeated independently twice with similar results. H&E hematoxylin-eosin, ICI immune checkpoint inhibitor.

Considering that the current diagnosis of ICI-induced colitis is primarily based on non-specific observations rather than on specific diagnostic markers [4, 5], it is sometimes difficult to differentiate ICI-induced colitis from other types of colitis. At present, the gold standard for diagnosing and monitoring ICI-induced colitis is colonoscopy [4, 5]. Several studies have revealed that endoscopically confirmed ulceration or pancolitis indicates steroid-refractory ICI-induced colitis that requires early intensive immunosuppression [9, 26–28]. However, although monitoring by repeat colonoscopy is recommended for individuals who are

refractory to immunosuppressive agents [4], frequent colonoscopy can be a physical burden on cancer patients. Blood tests, including complete blood count, comprehensive metabolic panel, C-reactive protein (CRP), and thyroid-stimulating hormone, are also recommended for noninvasive assessment of ICI-induced colitis [4, 5]. However, these factors are not specific to ICI-induced colitis, and moreover, it has been reported that the biochemical parameters, including CRP, albumin, and hemoglobin, did not correlate with the severity of ICI-induced colitis [28]. Several guidelines have suggested fecal calprotectin and lactoferrin as alternatives or adjuncts to endoscopic evaluation for monitoring ICI-induced colitis [4, 5]. However, fecal calprotectin levels could also be elevated in patients with malignant tumors in the GI tract [29, 30]. These studies highlight the challenges associated with the diagnosis and monitoring of ICI-induced colitis.

In this study, we showed that a part of the patients with ICI-induced colitis had anti-integrin αvβ6 autoantibodies. Based on these autoantibodies, an accurate diagnosis of ICI-induced colitis may help facilitate the early implementation of the appropriate treatment for ICI-induced colitis. In addition, patients with ICI-induced colitis with anti-integrin αvβ6 autoantibodies exhibited more severe symptoms than those without the autoantibodies. These findings suggest that anti-integrin αvβ6 autoantibodies may serve as a potential biomarker to identify life-threatening ICI-induced colitis, which requires more intensive immunosuppressive therapy. Together, this noninvasive marker may be useful in clinical decisions and monitoring the disease activity during therapy.

As for characteristics of anti-integrin αvβ6 autoantibodies, we found that both IgG subclass and immunoglobulin isotype of anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were similar to those identified in UC patients. Moreover, anti-integrin αvβ6 autoantibodies bound to the dimeric conformation of integrin αvβ6 and blocked integrin αvβ6-fibronectin binding via the RGD motif. These characteristics are also similar to those of anti-integrin αvβ6 autoantibodies in patients with UC [12]. These data suggest that the UC and ICI-induced colitis with anti-integrin αvβ6 autoantibodies may share a common pathophysiology, although it remains unclear whether anti-integrin αvβ6 autoantibodies have a pathological role. Nonetheless, using the same treatment strategy as UC, such as infliximab and vedolizumab, to treat patients with ICI-induced colitis with autoantibody appears reasonable. In addition, given that the pathogenesis and clinical manifestations of ICI-induced colitis are considered to be heterogeneous, autoantigens in ICI-induced colitis patients without anti-integrin αvβ6 autoantibodies, whose clinical manifestations are similar to Crohn's disease, or microscopic colitis, may be different from integrin αvβ6. Therefore, the measurement of anti-integrin αvβ6 autoantibodies might contribute to the classification of the ICI-induced colitis.

Interestingly, we found that integrin αvβ6 expression was observed in all tumors obtained from patients positive for anti-integrin αvβ6 autoantibodies. In contrast, only half of the autoantibody-negative cases exhibited such expression. These findings indicate that integrin αvβ6 in the primary tumor may be related to anti-integrin αvβ6 autoantibody production. However, further investigations are required in this regard, given the relatively frequent (50%) expression of integrin αvβ6 in the tumors of patients without anti-integrin αvβ6 autoantibodies.

There are some limitations of this study. The sample size used in this research was relatively small. Furthermore, this study did not include patients with mild ICI-induced colitis who had not undergone colonoscopy. Given the nature of the retrospective study, it should also be recognized that there is substantial heterogeneity in the clinical evaluation and management of ICI-induced colitis among institutions. A prospective study with a large number of patients is therefore needed to confirm our present findings. It may also be possible that patients with ICI-induced colitis with anti-integrin αvβ6 autoantibodies had

predisposing factors for UC before ICI treatment. Therefore, a future study that measures antibody titers at baseline before ICI administration is necessary.

In conclusion, this study revealed that anti-integrin $\alpha\text{v}\beta 6$ autoantibodies could be a potential biomarker for diagnosis and assessment of disease activity of ICI-induced colitis. Our findings suggest the importance of these autoantibodies for the classification and risk management of ICI-induced colitis. Further large-scale studies are warranted to confirm that anti-integrin $\alpha\text{v}\beta 6$ autoantibodies are a useful biomarker for high-risk ICI-induced colitis.

DATA AVAILABILITY

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

- Ribas A, Wolchik JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359:1350–5.
- Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer*. 2016;54:139–48.
- Martins F, Sofiya L, Sykietis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint. Inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol*. 2019;16:563–80.
- Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. *J Clin Oncol*. 2021;39:4073–126.
- Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2022;33:1217–38.
- Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, et al. Clinical, endoscopic, and histologic characteristics of Ipilimumab-associated Colitis. *Clin Gastroenterol Hepatol*. 2016;14:836–42.
- Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. *J Crohns Colitis*. 2016;10:395–401.
- Kubo K, Kato M, Mabe K. Nivolumab-associated colitis mimicking ulcerative colitis. *Clin Gastroenterol Hepatol*. 2017;15:A35–A36.
- Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. *J Immunother Cancer*. 2018;6:95.
- Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, et al. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. *BMC Gastroenterol*. 2018;18:135.
- Kikuchi H, Sakuraba H, Akemoto Y, Murai Y, Fukutoku Y, Asari T, et al. A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. *Immunol Med*. 2019;42:39–44.
- Kuwada T, Shiokawa M, Kodama Y, Ota S, Kakiuchi N, Nannya Y, et al. Identification of an anti-Integrin $\alpha\text{v}\beta 6$ autoantibody in patients with ulcerative colitis. *Gastroenterology*. 2021;160:2383–94.e21.
- Uzzan M, Martin JC, Mesin L, Livanos AE, Castro-Dopico T, Huang R, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. *Nat Med*. 2022;28:766–79.
- Rydell N, Ekoff H, Hellström PM, Movérare R. Measurement of serum IgG Anti-Integrin $\alpha\text{v}\beta 6$ autoantibodies is a promising tool in the diagnosis of ulcerative colitis. *J Clin Med*. 2022;11:1881.
- Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. *Cell*. 1992;69:11–25.
- Breuss JM, Gallo J, Delisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. *J Cell Sci*. 1995;108:2241–51.
- Yu Y, Chen S, Lu GF, Wu Y, Mo L, Liu ZQ, et al. Alphavbeta6 is required in maintaining the intestinal epithelial barrier function. *Cell Bio Int*. 2014;38:777–81.
- Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. *Curr Drug Targets*. 2009;10:645–52.
- Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf 2018.
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med*. 1987;317:1625–9.
- Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *J Crohns Colitis*. 2017;11:649–70.
- Shiokawa M, Kodama Y, Sekiguchi K, Kuwada T, Tomono T, Kuriyama K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. *Sci Transl Med*. 2018;10:eaq0997.
- Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, Dolinski BM, et al. Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. *J Biol Chem*. 2004;279:17875–87.
- Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell*. 2002;110:673–87.
- Busk M, Pytela R, Sheppard D. Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. *J Biol Chem*. 1992;267:5790–6.
- Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. *Inflamm Bowel Dis*. 2018;24:1695–705.
- Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. *ESMO Open*. 2018;3:e000278.
- Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? *Br J Cancer*. 2020;123:207–15.
- Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. *Gut*. 2001;49:402–8.
- Turvill J, Aghahoseini A, Sivarajasingham N, Abbas K, Choudhry M, Polyzois K, et al. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study. *Br J Gen Pr*. 2016;66:e499–e506.

ACKNOWLEDGEMENTS

We thank the patients and healthy volunteers who provided serum samples for this study. We also thank Shino Yamaguchi, Taichi Ito, and Toshiko Kumashiro for their extensive technical support and Editage (www.editage.com) for English language editing.

AUTHOR CONTRIBUTIONS

MY, MS, HK and HS conceived, designed, and supervised the study; MY, HK, YM, NO, TM, KO, MO, YK, and HH collected the samples and data; MY, H Kitamoto, M Okabe, and HY analyzed the data with the assistance of TK, YN, RN, IT, M Yasuda, KC, SM, H Yoshida, SO, TN, HO, TH, NK, T Matsumori, SY, and NU; MY, MS, and HK wrote the first draft of the manuscript and revised it with considerable input from TC and HS.

FUNDING

This work was supported by a grant from the Japanese Society of Gastroenterology and JSPS KAKENHI (22J14815).

COMPETING INTERESTS

The authors declare no competing interests

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

With regards to patient involvement, this study was conducted in compliance with the Helsinki Declaration and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The protocol was approved by the Human Ethics Review Committee of Kyoto University Hospital (approval no. R1004). All participants provided written informed consent.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41416-024-02647-1>.

Correspondence and requests for materials should be addressed to Masahiro Shiokawa or Hisato Kawakami.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024